Neil Horning, MD
Pulmonary Disease · Des Moines, IANPI 1770569154
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.0%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Boehringer Ingelheim accounts for 69.1% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2020 at $8,528 and has fallen 88.8% since, to $957 in 2025. Among pulmonary disease clinicians in IA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 51 payments — averaging $300.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$11K
- GSK$3K
- Genentech USA, Inc.$318
- United Therapeutics Corporation$271
- Penumbra, Inc.$209
- Abiomed$125
- plus $767 from 10 others
What the payments were for
- Consulting fees$4,15227%
- Speaking & faculty fees$8,26554%
- Food & beverage$2,86419%
- Education$260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 27 | $10,573 |
| GSK | 3 | $3,044 |
| Genentech USA, Inc. | 3 | $318 |
| United Therapeutics Corporation | 2 | $271 |
| Penumbra, Inc. | 1 | $209 |
| Abiomed | 1 | $125 |
| Regeneron Healthcare Solutions, Inc. | 1 | $125 |
| Sanofi | 1 | $121 |
| La Jolla Pharmaceutical Company | 1 | $105 |
| Actelion Pharmaceuticals US, Inc. | 1 | $100 |
| Grifols USA, LLC | 2 | $83 |
| Insmed, Inc. | 4 | $80 |
| Inari Medical, Inc. | 1 | $71 |
| Merck | 1 | $34 |
| Amgen | 1 | $32 |
| Electromed, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,307 in reported general payments places this provider in the 90th percentile of 110 pulmonary disease providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tyvaso DpiTreprostinil | 15 | $341,063 |
| OpsumitMacitentan | 15 | $183,720 |
| AdempasRiociguat | 11 | $154,964 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 103 | $78,348 |
| Orenitram ErTreprostinil Diolamine | 23 | $47,558 |
| Breo ElliptaFluticasone/Vilanterol | 90 | $37,885 |
| Spiriva RespimatTiotropium Bromide | 67 | $36,088 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 45 | $29,928 |
| Incruse ElliptaUmeclidinium Bromide | 55 | $19,237 |
| Pirfenidone | 12 | $18,969 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 37 | $18,621 |
| Tadalafil | 32 | $17,581 |
| Bosentan | 14 | $17,452 |
| Spiriva HandihalerTiotropium Bromide | 17 | $13,121 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 79 | $9,188 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Bosentan | $100 | $201,17229 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $3,044 | $171,803320 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $10,573 | $54,709104 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 110 pulmonary disease providers in Iowa.
Other pulmonary disease in Des Moines
- Shrey VelaniDes Moines$18K
- Jason WittmerDes Moines$10K
- Bradley WilcoxDes Moines$7K
- Blair WesterlyDes Moines$7K
- Eric AsbeDes Moines$4K
- Maxwell CosmicDes Moines$3K
- Anthony GrecoDes Moines$3K
- Lucas Silqueira Hickson CruzDes Moines$2K
- Maksym PuliaievDes Moines$2K
- Bryon JohnsonDes Moines$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.